P53 Gene Polymorphisms and Breast Cancer Risk in Arab Women

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2010 May 6

PMID 20443084

Citations 24

Authors

Shafika Alawadi

Lina Ghabreau

Mervat Alsaleh

Zainab Abdulaziz

Mohamed Rafeek

Nizar Akil

Moussa Alkhalaf

Affiliations

Soon will be listed here.

Abstract

The association between polymorphisms in the p53 tumor suppressor gene and breast cancer risk has been studied in many human populations with conflicting conclusions. However, similar studies in Arab women are not available, and the status of these polymorphisms in this ethnic population is not known. We investigated the status of four known p53 gene polymorphisms and their possible role in breast cancer risk in Arab women. Genotyping was performed for 288 breast cancer women and 188 controls to determine Pro47Ser, Arg72Pro, Intron 3 Ins16 bp and intron 6 (G > C) polymorphisms. The p53 variant Pro47Ser was detected only in one Kuwaiti breast cancer patient and was not detected in any of the control subjects. Frequency of Arg/Arg at codon 72 was 26.6% in controls and 28.1% in patients, Arg/Pro frequency was 59.6% in controls and 69.4% in patients, the Pro/Pro genotype was 13.8% in controls and 2.4% in patients. We observed that women with Pro/Pro genotype have decreased risk for developing breast cancer (OR=0.166, 95% CI=0.067-0.411, p<0.001). The intron 3 genotypes were A1/A1 (48.9%), A1/A2 (40.6%) and A2/A2 (10.5%) in controls and A1/A1(42.4%), A1/A2 (52.8%) and A2/A2 (4.8%) in cases. The intron 6 genotypes were 92.4% (GG), 7.6% (GC) and 0% (CC) in controls and 96.5% (GG), 3.5% (GC) and 0% (CC) in cases. No statistically significant differences between patients and controls were observed for intron 3 and intron 6 polymorphisms. Our data show that proline homozygosity at p53 codon 72 is associated with decreased breast cancer risk in Arab women.

Citing Articles

Breast Cancer in the Arabian Gulf Countries.

Al-Shamsi H, Abdelwahed N, Abyad A, Abu-Gheida I, Afrit M, Abu ElFuol T Cancers (Basel). 2023; 15(22).

PMID: 38001658 PMC: 10670541. DOI: 10.3390/cancers15225398.

Association of Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men.

Duncan A, Nousome D, Ricks R, Kuo H, Ravindranath L, Dobi A Biomedicines. 2023; 11(5).

PMID: 37239075 PMC: 10216554. DOI: 10.3390/biomedicines11051404.

Association of and genes polymorphisms with familial breast cancer in patients of Khyber Pakhtunkhwa, Pakistan.

Rahim A, Zakiullah , Jan A, Ali J, Khuda F, Muhammad B Afr Health Sci. 2023; 22(3):145-154.

PMID: 36910346 PMC: 9993321. DOI: 10.4314/ahs.v22i3.17.

p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.

Diakite B, Kassogue Y, Dolo G, Wang J, Neuschler E, Kassogue O BMC Med Genet. 2020; 21(1):206.

PMID: 33076844 PMC: 7574232. DOI: 10.1186/s12881-020-01133-8.

Association of PIN3 16-bp duplication polymorphism of TP53 with breast cancer risk in Mali and a meta-analysis.

Diakite B, Kassogue Y, Dolo G, Kassogue O, Keita M, Joyce B BMC Med Genet. 2020; 21(1):142.

PMID: 32620097 PMC: 7333399. DOI: 10.1186/s12881-020-01072-4.

References

Dumont P, Leu J, Della Pietra 3rd A, George D, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-65. DOI: 10.1038/ng1093. View

Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H . A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci. 2003; 10(4):430-5. DOI: 10.1007/BF02256434. View

Vousden K, Lane D . p53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8(4):275-83. DOI: 10.1038/nrm2147. View

Felley-Bosco E, Weston A, Cawley H, BENNETT W, Harris C . Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet. 1993; 53(3):752-9. PMC: 1682404. View

Akkiprik M, Sonmez O, Gulluoglu B, Caglar H, Kaya H, Demirkalem P . Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer. Pathol Oncol Res. 2008; 15(3):359-68. DOI: 10.1007/s12253-008-9129-6. View

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian S, Hainaut P . Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28(6):622-9. DOI: 10.1002/humu.20495. View

Marsh A, Spurdle A, Turner B, Fereday S, Thorne H, Pupo G . The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res. 2001; 3(5):346-9. PMC: 57805. DOI: 10.1186/bcr319. View

Whibley C, Pharoah P, Hollstein M . p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009; 9(2):95-107. DOI: 10.1038/nrc2584. View

Alkhalaf M, Al-Bustan S, Hamoda H, Abdella N . Polymorphism of p53 gene codon 72 in Kuwaiti with coronary artery disease and diabetes. Int J Cardiol. 2006; 115(1):1-6. DOI: 10.1016/j.ijcard.2006.01.029. View

10.

De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, Pensotti V . The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev. 2008; 32(2):140-3. DOI: 10.1016/j.cdp.2008.06.003. View

11.

Cavallone L, Arcand S, Maugard C, Ghadirian P, Mes-Masson A, Provencher D . Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer. 2008; 8:96. PMC: 2329651. DOI: 10.1186/1471-2407-8-96. View

12.

Fiszer-Maliszewska L, Kazanowska B, Kusnierczyk P, Manczak M, Niepieklo W, Pochron-Zeman B . Is p53 intronic variant G13964C associated with predisposition to cancer?. J Appl Genet. 2003; 44(4):547-52. View

13.

Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum I, Chang-Claude J . Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002; 12(3):269-72. DOI: 10.1097/00008571-200204000-00012. View

14.

Langerod A, Bukholm I, Bregard A, Lonning P, Andersen T, Rognum T . The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1684-8. View

15.

Siddique M, Sabapathy K . Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006; 25(25):3489-500. DOI: 10.1038/sj.onc.1209405. View

16.

Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R . Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008; 8:32. PMC: 2254432. DOI: 10.1186/1471-2407-8-32. View

17.

Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G . Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol. 2008; 29(3):145-51. DOI: 10.1159/000143400. View

18.

Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L . p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996; 17(6):1313-6. DOI: 10.1093/carcin/17.6.1313. View

19.

Singh V, Rastogi N, Mathur N, Singh K, Singh M . Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol. 2007; 18(1):48-57. DOI: 10.1016/j.annepidem.2007.06.006. View

20.

Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z . p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 2005; 11(20):7328-33. DOI: 10.1158/1078-0432.CCR-05-0507. View